Biodesign Israel News
3 articles
growth-positive
ביודיזיין-ישראל מטפחת מנהיגי חדשנות בבריאות
Biodesign-Israel, a national academy for innovation leaders in health-tech, is working to shorten the long lifecycle of technological innovation in the health sector. The company focuses on acquiring useful tools for in-depth research of medical needs and patient pathways, from home to hospitals. The company was founded by Dr. Yona Vaisbuch, who was trained in Stanfords Biodesign program. Biodesign-Israel offers various courses and workshops, including a flagship course, Biodesign Innovation Course, in collaboration with the Technion, the Faculty of Biomedical Engineering, and the University of Haifa.
PartnersExpand
growth-positive
לראשונה בישראל: מרצים מסטנפורד יעבירו סדנת חדשנות
The Technions Continuing Education Unit, in collaboration with Rambam Medical Center and BioDesign Israel, will host lecturers from Stanford University who will conduct a workshop on innovation development in the HealthTech world. The workshop, intended for managers, will provide participants with a new perspective on the ability to lead innovation and turn a need into an invention. The program will take place over four days at the Technion campus in Sarona Tel Aviv. Among the senior lecturers coming from Stanford University is the international lecturer Prof. Robson Capasso.
Partners
growth-positive
רמב"ם ביודיזיין: מחדד את ההבדל ביין הייטק לביומד - וואלה! כסף
Rambam BioDesign, a collaborative initiative involving Rambam Health Care Campus and Stanford University, has concluded its first cycle. The program focuses on developing innovative medical solutions by combining expertise from doctors, engineers, and business professionals. Key developments include a non-invasive device for monitoring fetal oxygen levels to reduce unnecessary C-sections, and a wristband for continuous glucose monitoring and automatic insulin delivery for diabetes patients. The initiative emphasizes a patient-centric approach, starting with identifying patient needs before developing technology. The program has garnered interest from investors and universities, highlighting its potential to revolutionize medical innovation.
Partners
